{"id":"ibandronate","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Back pain","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Pain in extremity","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["Achalasia of esophagus","Acute nephropathy","Acute peptic ulcer","Aseptic necrosis of bone of jaw","Bed-ridden","Bone pain","Duodenitis","Dysphagia","Esophageal dysmotility","Esophagitis","Fracture of femur","Gastritis","Heartburn","Hypocalcemia","Invasive Dental Procedure","Joint pain","Muscle pain","Primary malignant neoplasm","Stricture of esophagus","Swallowing painful","Tooth disorder","Ulcer of esophagus","Vitamin D deficiency"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Serious adverse reactions (overall incidence)","drugRate":"23%","severity":"serious"},{"effect":"Iritis","drugRate":"","severity":"serious"},{"effect":"Scleritis","drugRate":"","severity":"serious"},{"effect":"Ocular inflammation","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL3989569","moleculeType":"Small molecule","molecularWeight":"359.23"},"aliases":["Boniva","Bonviva/Boniva","Bonviva","Bondronat","BONIVA®"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$4.3482/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,587","description":"IBANDRONATE SODIUM 150 MG TAB","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[],"_dailymed":{"setId":"86c0b4ae-5e38-4efe-88af-50ac560e294f","title":"IBANDRONATE SODIUM TABLET, FILM COATED [AUROBINDO PHARMA LIMITED]"},"ecosystem":[],"mechanism":{"target":"Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase"},"_scrapedAt":"2026-03-27T23:47:48.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"},{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Hypercalcemia","diseaseId":"hypercalcemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Postmenopausal osteoporosis","diseaseId":"postmenopausal-osteoporosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07406685","phase":"PHASE4","title":"The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-03-17","conditions":"Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis","enrollment":52},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT07043608","phase":"PHASE2","title":"Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases","status":"NOT_YET_RECRUITING","sponsor":"Kelly Fitzgerald, MD","startDate":"2025-09-30","conditions":"Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic","enrollment":20},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT04321837","phase":"PHASE2","title":"Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-02-05","conditions":"Osteoporosis, Postmenopausal","enrollment":60},{"nctId":"NCT02635997","phase":"","title":"Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America","status":"COMPLETED","sponsor":"Pontifical Catholic University of Argentina","startDate":"2013-01","conditions":"Osteoporosis","enrollment":425},{"nctId":"NCT06022237","phase":"NA","title":"Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-09-01","conditions":"Hepatic Osteodystrophy, Liver Cirrhosis","enrollment":80},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314},{"nctId":"NCT05266261","phase":"NA","title":"Use of Ibandronate in Diabetic Patients","status":"COMPLETED","sponsor":"Yeouido St. Mary's Hospital","startDate":"2018-10-01","conditions":"Osteoporosis, Postmenopausal, Type 2 Diabetes","enrollment":121},{"nctId":"NCT01077817","phase":"","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-02-26","conditions":"Esophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma","enrollment":684815},{"nctId":"NCT00092053","phase":"PHASE3","title":"Study of Investigational Drug in Osteoporosis (MK-0217-908)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12","conditions":"Postmenopausal Osteoporosis","enrollment":203},{"nctId":"NCT03186131","phase":"PHASE2","title":"Efficacy of Oral Ibandronate in Osteoporosis","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2017-10-12","conditions":"Osteoporosis","enrollment":100},{"nctId":"NCT02156999","phase":"PHASE4","title":"Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2014-06","conditions":"Osteoporosis","enrollment":100},{"nctId":"NCT00127205","phase":"PHASE3","title":"S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2005-07","conditions":"Breast Cancer","enrollment":6097},{"nctId":"NCT02616744","phase":"PHASE2","title":"Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2011-01","conditions":"Breast Cancer","enrollment":171},{"nctId":"NCT00662077","phase":"PHASE4","title":"Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort","status":"WITHDRAWN","sponsor":"Germans Trias i Pujol Hospital","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT01406613","phase":"","title":"Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-03","conditions":"Postmenopausal Osteoporosis","enrollment":86},{"nctId":"NCT02731040","phase":"","title":"Exome Sequencing for Atypical Femoral Fractures","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04","conditions":"Atypical Femoral Fractures, Osteoporosis, Bisphosphonate Therapy","enrollment":38},{"nctId":"NCT00824993","phase":"PHASE3","title":"Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-12-09","conditions":"Hematological Malignancies","enrollment":78},{"nctId":"NCT00405392","phase":"PHASE4","title":"Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-22","conditions":"Osteoporosis, Postmenopausal","enrollment":365},{"nctId":"NCT00048061","phase":"PHASE3","title":"MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-04","conditions":"Post Menopausal Osteoporosis","enrollment":1609},{"nctId":"NCT00666627","phase":"PHASE2","title":"Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-04","conditions":"Post-menopausal Osteoporosis","enrollment":410},{"nctId":"NCT00099203","phase":"PHASE3","title":"A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Pain, Bone Neoplasm, Neoplasm Metastasis","enrollment":163},{"nctId":"NCT00478270","phase":"PHASE2","title":"A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Pain, Bone Neoplasm, Neoplasm Metastasis","enrollment":""},{"nctId":"NCT00099177","phase":"PHASE3","title":"A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-08","conditions":"Pain, Bone Neoplasm, Neoplasm Metastasis","enrollment":96},{"nctId":"NCT00081653","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-05","conditions":"Post-Menopausal Osteoporosis","enrollment":719},{"nctId":"NCT00327990","phase":"PHASE4","title":"Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Osteoporosis","enrollment":300},{"nctId":"NCT02114489","phase":"PHASE3","title":"Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis","status":"TERMINATED","sponsor":"Brigitte Jolles, MD","startDate":"2014-06","conditions":"Aseptic Hip Necrosis, Hip Necrosis","enrollment":8},{"nctId":"NCT00545207","phase":"PHASE3","title":"A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"Post-Menopausal Osteopenia","enrollment":150},{"nctId":"NCT00545090","phase":"PHASE4","title":"ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-08","conditions":"Post Menopausal Osteoporosis","enrollment":561},{"nctId":"NCT00148915","phase":"PHASE4","title":"A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-08","conditions":"Osteoporosis","enrollment":98},{"nctId":"NCT02564107","phase":"PHASE4","title":"A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":48},{"nctId":"NCT02598453","phase":"PHASE4","title":"PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-01","conditions":"Postmenopausal Osteoporosis","enrollment":545},{"nctId":"NCT02604836","phase":"PHASE4","title":"A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Postmenopausal Osteoporosis","enrollment":1711},{"nctId":"NCT02598440","phase":"PHASE4","title":"A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Postmenopausal Osteoporosis","enrollment":341},{"nctId":"NCT01128257","phase":"","title":"A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-04","conditions":"Postmenopausal Osteoporosis","enrollment":6054},{"nctId":"NCT00493532","phase":"","title":"A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.","status":"NO_LONGER_AVAILABLE","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Postmenopausal Osteoporosis","enrollment":""},{"nctId":"NCT02561039","phase":"PHASE3","title":"A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":97},{"nctId":"NCT00545909","phase":"PHASE4","title":"BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03","conditions":"Postmenopausal Osteoporosis","enrollment":585},{"nctId":"NCT02553850","phase":"","title":"An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Breast Cancer","enrollment":442},{"nctId":"NCT01429675","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-08","conditions":"Healthy","enrollment":105},{"nctId":"NCT01581320","phase":"PHASE3","title":"Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-12","conditions":"Postmenopausal Women With Osteoporosis","enrollment":201},{"nctId":"NCT01577849","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2012-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT02948881","phase":"PHASE4","title":"A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08","conditions":"Osteoporosis","enrollment":100},{"nctId":"NCT00545779","phase":"PHASE3","title":"BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Post-Menopausal Osteoporosis","enrollment":677},{"nctId":"NCT00545363","phase":"PHASE4","title":"A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Postmenopausal Osteoporosis","enrollment":716},{"nctId":"NCT00377234","phase":"PHASE4","title":"A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Post Menopausal Osteoporosis","enrollment":356},{"nctId":"NCT02739594","phase":"PHASE3","title":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-02","conditions":"Multiple Myeloma","enrollment":89},{"nctId":"NCT00545051","phase":"PHASE4","title":"A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Postmenopausal Osteoporosis","enrollment":140},{"nctId":"NCT00303485","phase":"PHASE4","title":"A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-02","conditions":"Post Menopausal Osteoporosis","enrollment":67},{"nctId":"NCT02716792","phase":"PHASE3","title":"A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-01","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":334},{"nctId":"NCT02598934","phase":"PHASE4","title":"A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-08","conditions":"Post Menopausal Osteoporosis","enrollment":308},{"nctId":"NCT00493623","phase":"PHASE3","title":"BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Osteoporosis","enrollment":68},{"nctId":"NCT00492843","phase":"PHASE4","title":"Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis","status":"TERMINATED","sponsor":"Chinese Society of Lung Cancer","startDate":"2007-07","conditions":"Lung Cancer","enrollment":20},{"nctId":"NCT00048074","phase":"PHASE3","title":"DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-06","conditions":"Post Menopausal Osteoporosis","enrollment":1395},{"nctId":"NCT00129623","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-12","conditions":"Post-Menopausal Osteopenia","enrollment":160},{"nctId":"NCT02553707","phase":"PHASE4","title":"A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":182},{"nctId":"NCT00532220","phase":"PHASE3","title":"Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2007-12","conditions":"Osteonecrosis of the Knee, Bone Marrow Edema of the Knee","enrollment":30},{"nctId":"NCT02528747","phase":"","title":"A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-01","conditions":"Metastatic Breast Cancer","enrollment":582},{"nctId":"NCT00545480","phase":"PHASE4","title":"SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07","conditions":"Post Menopausal Osteoporosis","enrollment":596},{"nctId":"NCT01290094","phase":"PHASE3","title":"A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04","conditions":"Post Menopausal Osteoporosis","enrollment":41},{"nctId":"NCT01287533","phase":"PHASE4","title":"Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids","status":"COMPLETED","sponsor":"Yeong-Wook Song","startDate":"2010-04","conditions":"Rheumatoid Arthritis, Osteoporosis, Osteopenia","enrollment":167},{"nctId":"NCT00446589","phase":"PHASE4","title":"The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density","status":"TERMINATED","sponsor":"Papageorgiou General Hospital","startDate":"2006-07","conditions":"Osteoporosis","enrollment":19},{"nctId":"NCT02271204","phase":"","title":"Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Clinic of Endocrinology and Metabolic Disorders, Macedonia","startDate":"2009-03","conditions":"Osteoporosis","enrollment":700},{"nctId":"NCT02249741","phase":"PHASE4","title":"Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation","status":"COMPLETED","sponsor":"Dr. Ashish Kumar","startDate":"2012-08","conditions":"Cirrhosis","enrollment":47},{"nctId":"NCT00196859","phase":"PHASE3","title":"Study in Elderly Patients With Early Breast Cancer (ICE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-06","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00196872","phase":"PHASE3","title":"A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-07","conditions":"Breast Cancer","enrollment":3000},{"nctId":"NCT01376102","phase":"","title":"BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Osteoporosis","enrollment":657},{"nctId":"NCT00091832","phase":"PHASE2","title":"Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-09","conditions":"Breast Cancer, Metastases, Bone Metastases in Subjects With Advanced Breast Cancer","enrollment":255},{"nctId":"NCT00502736","phase":"PHASE2","title":"A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":13},{"nctId":"NCT00767169","phase":"PHASE2","title":"Bisphosphonate-coated Dental Implants","status":"COMPLETED","sponsor":"University Hospital, Linkoeping","startDate":"2008-10","conditions":"Edentatio (Toothlessness)","enrollment":16},{"nctId":"NCT00301886","phase":"PHASE3","title":"S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2006-05","conditions":"Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer","enrollment":""},{"nctId":"NCT00683163","phase":"PHASE2, PHASE3","title":"PTH & Ibandronate Combination Study (PICS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-05","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT00082927","phase":"PHASE3","title":"Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2003-04","conditions":"Metastatic Cancer, Pain, Prostate Cancer","enrollment":580},{"nctId":"NCT00873808","phase":"","title":"S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-10","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00326820","phase":"PHASE3","title":"Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer","status":"UNKNOWN","sponsor":"Wales Cancer Trials Unit","startDate":"2006-01","conditions":"Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer","enrollment":1404},{"nctId":"NCT00936897","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-07","conditions":"Postmenopausal Osteoporosis","enrollment":833},{"nctId":"NCT01381393","phase":"","title":"BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Osteoporosis","enrollment":659},{"nctId":"NCT00447915","phase":"PHASE3","title":"Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-03","conditions":"Primary Osteoporosis","enrollment":1265},{"nctId":"NCT01627886","phase":"PHASE1","title":"Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-09","conditions":"Healthy","enrollment":100},{"nctId":"NCT00668330","phase":"PHASE4","title":"Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2007-04","conditions":"Systemic Lupus Erythematosus","enrollment":40},{"nctId":"NCT00551174","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Post-Menopausal Osteoporosis","enrollment":781},{"nctId":"NCT00503113","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-07","conditions":"Post-Menopausal Osteoporosis","enrollment":801},{"nctId":"NCT00423384","phase":"PHASE2, PHASE3","title":"Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.","status":"UNKNOWN","sponsor":"Smerud Medical Research International AS","startDate":"2007-01","conditions":"Renal Transplant","enrollment":130},{"nctId":"NCT00397839","phase":"PHASE3","title":"The Effect Of Oral Ibandronate In Male Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Male Osteoporosis","enrollment":135},{"nctId":"NCT00271713","phase":"PHASE4","title":"Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-03","conditions":"Osteoporosis, Postmenopausal","enrollment":70},{"nctId":"NCT00381368","phase":"PHASE2","title":"Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients","status":"UNKNOWN","sponsor":"University of Turku","startDate":"2006-10","conditions":"Breast Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":365,"reaction":"ARTHRALGIA"},{"count":321,"reaction":"NAUSEA"},{"count":319,"reaction":"DIARRHOEA"},{"count":293,"reaction":"FEMUR FRACTURE"},{"count":282,"reaction":"HEADACHE"},{"count":261,"reaction":"FATIGUE"},{"count":256,"reaction":"FALL"},{"count":253,"reaction":"PAIN"},{"count":247,"reaction":"PAIN IN EXTREMITY"},{"count":222,"reaction":"BACK PAIN"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20230607","type":"SUPPL","sponsor":"MACLEODS PHARMS LTD","applicationNumber":"ANDA206887"},{"date":"20171031","type":"ORIG","sponsor":"MACLEODS PHARMS LTD","applicationNumber":"ANDA206887"},{"date":"20260203","type":"SUPPL","sponsor":"MACLEODS PHARMS LTD","applicationNumber":"ANDA206887"},{"date":"20241008","type":"SUPPL","sponsor":"MACLEODS PHARMS LTD","applicationNumber":"ANDA206887"},{"date":"20150715","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA078997"},{"date":"20231019","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA078997"},{"date":"20150715","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA078997"},{"date":"20130308","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA078997"},{"date":"20120430","type":"ORIG","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA078997"},{"date":"20260203","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA078997"},{"date":"20231019","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA078997"},{"date":"20200619","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA078997"},{"date":"20230215","type":"SUPPL","sponsor":"ORBION PHARMS","applicationNumber":"ANDA078998"},{"date":"20150715","type":"SUPPL","sponsor":"ORBION PHARMS","applicationNumber":"ANDA078998"},{"date":"20120319","type":"ORIG","sponsor":"ORBION PHARMS","applicationNumber":"ANDA078998"},{"date":"20150715","type":"SUPPL","sponsor":"ORBION PHARMS","applicationNumber":"ANDA078998"},{"date":"20260203","type":"SUPPL","sponsor":"ORBION PHARMS","applicationNumber":"ANDA078998"},{"date":"20260203","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA202671"},{"date":"20250806","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA202671"},{"date":"20140902","type":"ORIG","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA202671"},{"date":"20150902","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA202671"},{"date":"20180406","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA202671"},{"date":"20180406","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA202671"},{"date":"20150819","type":"ORIG","sponsor":"EUGIA PHARMA","applicationNumber":"ANDA205332"},{"date":"20200731","type":"SUPPL","sponsor":"EUGIA PHARMA","applicationNumber":"ANDA205332"},{"date":"20260203","type":"SUPPL","sponsor":"EUGIA PHARMA","applicationNumber":"ANDA205332"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Bone"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Ibandronate","genericName":"Ibandronate","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}